This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on the prevention and treatment of cardiovascular disease—if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
FletcherS.W., ColditzG.A.Failure of estrogen plus progestin therapy for prevention [editorial]. JAMA.2002; 288: 366–8.
2.
MendelsohnM.E., KarasR.H.The protective effects of estrogen on the cardiovascular system. N Engl J Med.1999; 340; 1801–11.
3.
MoscaL.The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med.2000; 160: 2263–72.
4.
The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: The Writing Group for the PEPI trial.Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA.1995; 273: 199–208.
5.
BushT.L.The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci.1990; 592: 263–71.
6.
GradyD., RubinS.M., PetittiD.B.Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med.1992; 117; 1016–37.
7.
StampferM.J., ColditzG.A.Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med.1991; 20: 47–63.
8.
Barrett-ConnorE., GradyD.Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health.1998; 19: 55–72.
9.
SullivanJ.M., VanderZ.R., HughesJ.P.Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med.1990; 150: 2557–62.
10.
NewtonK.M., LaCroixA.Z., McKnightB.Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol.1997; 145: 269–77.
11.
O'KeefeJ.H.Jr., KimS.C., HallR.R.Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol.1997; 29: 1–5.
12.
GrodsteinF., StampferM.J., MansonJ.E.Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med.1996; 335: 453–61.
13.
GrodsteinF., MansonJ.E., ColditzG.A.A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med.2000; 133: 933–41.
14.
GrodsteinF., MansonJ.E., StampferM.J.Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: A prospective observational study. Ann Intern Med.2001; 135: 1–8.
15.
HulleyS., GradyD., BushT.for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA.1998; 280: 605–13.
16.
GradyD., HerringtonD., BittnerV.for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin replacement study follow-up (HERS II). JAMA.2002; 288: 49–57.
17.
HulleyS., FurbergC., Barrett-ConnorE.for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin replacement study follow-up (HERS II). JAMA.2002; 288: 58–66.
18.
HerringtonD.M., ReboussinD.M., BrosnihanK.B.Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med.2000; 343: 522–9.
19.
MoscaL., CollinsP., HerringtonD.M.Hormone replacement therapy and cardiovascular disease. A statement for Healthcare Professionals from the American Heart Association. Circulation.2001; 104: 499–503.
20.
Writing Group for the Women's Health Initiative Investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA.2002; 288: 321–33.
21.
CollinsP.Clinical cardiovascular studies of hormone replacement therapy. Am J Cardiol.2002; 90(suppl): 30F–34F.
22.
ViscoliC.M., BrassL.M., KernanW.N.Estrogen after ischemic stroke: Effect of estrogen replacement on risk of recurrent stroke and death in the Women's Estrogen for Stroke Trial (WEST) [abstract]. Stroke.2001; 32: 329.
23.
LaceyJ.V.Jr., MinkP.J., LubinJ.H.Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA.2002; 288: 334–41.
HumphreyL.L., ChanB.K., SoxH.C.Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med.2002; 137: 273–84.
26.
NelsonH.D.Assessing benefits and harms of hormone replacement therapy: Clinical applications. JAMA.2002; 288: 882–4.
27.
MoscaL., Barrett-ConnorE., WengerN.Design and methods of the Raloxifene Use for the Heart (RUTH) Study. Am J Cardiol.2001; 88: 392–5.
28.
HerringtonD.M., VittinghoffE., LinF.Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation.2002; 105: 2962–7.
29.
RejnmarkL., BuusN.H., VestergaardP.Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur J Clin Invest.2002; 32: 581–9.
